Acute viral gastroenteritis: a brief review of current research and experience with antiviral drugs based on technologically processed antibodies

This article discusses the problem of acute viral gastroenteritis (AVGE), including aspects of immunopathogenesis that are significant for effective therapy and prevention. It also summarizes the results of randomized clinical trials assessing the efficacy of technologically processed purified antibodies (Anaferon® for children, Ergoferon®). We describe our own experience with Ergoferon® evaluated in a an open-label study involving 94 AVGE patients aged 1 to 10 years. Children who received Ergoferon® demonstrated rapid resolution of symptoms and normalization of body temperature 3–3.5 days after treatment initiation. Resolution of vomiting was achieved during the first 2 days of therapy in most of the patients. Median duration of diarrhea was 3.5–4 days, with a trend to a little bit longer diarrhea period in patients in patients aged 1–3 years. None of the patients developed complications or aggravation by the moment of discharge from the hospital (day 5–6 of treatment); all children were cured. The therapy was well tolerated by patients; none of them reported adverse events. Our findings suggest that drugs based on technologically processed affine purified antibodies are effective are effective and can be used in comprehensive treatment for acute viral gastroenteritis in children to ensure active defense against viruses, support the immune system, and alleviate symptoms via the anti-inflammatory effect. Key words: acute viral gastroenteritis, Ergoferon, Anaferon for children, treatment